Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345188 · ClinicalTrials.gov registry record · Phase 4
Ranolazine in Ischemic Cardiomyopathy
A Phase 4 study, sponsored by Midwest Cardiovascular Research Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01345188: Completed Phase 4 study, sponsored by Midwest Cardiovascular Research Foundation.
NCT01345188 is a Phase 4 study that has completed, run by Midwest Cardiovascular Research Foundation. The registered enrollment target is 28 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01345188, a Phase 4 study, has completed, sponsored by Midwest Cardiovascular Research Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.
Primary Outcome
Anginal frequency as assessed by Seattle Angina Questionnaire. Scoring is done by assessing responses on an ordinal value. Anginal score is scored by the patient by selecting a number from 0 to 100 with low score indicates more anginal frequency. The mean of the the scores of all patients analyzed were compared between placebo and Ranolazine.
Interventions
- DRUG Placebo
- DRUG Ranexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
What the finished NCT01345188 record still lists
NCT01345188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01345188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01345188 about?
NCT01345188 is a clinical study titled "Ranolazine in Ischemic Cardiomyopathy". Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to block...
What is the current status of trial NCT01345188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01345188?
The interventions under investigation include: Placebo (DRUG), Ranexa (DRUG).
Who is sponsoring clinical trial NCT01345188?
This trial is sponsored by Midwest Cardiovascular Research Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01345188's enrollment target sits among peer trials
28 1635th of 2000 higher than 350 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia